LINK-002

LINK-002 is a preclinical-stage product developed by LinkGevity using its AI-driven Anti-Necrotics™ platform. It is designed to inhibit necrosis, with reported efficacy of approximately 90% in blocking cell death. The product targets two primary non-clinical applications: the lab reagent market and tissue engineering. In the lab reagent market, it aims to improve the harvesting and extended viability of primary cells by reducing necrosis in cell culture media. In tissue engineering, it addresses the challenge of necrotic cores in complex lab-grown tissues and organs, potentially enabling the development of bioengineered organs for medical treatments and space missions.